Aligos Therapeutics, Inc.

ALGS

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001799448

SEC filings (opens in a new tab)

No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Q4 2021 vs. Q3 2021

How the institutions holding Aligos Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021 All holders in Q3 2021

13F holders of ALGS: Q3 2021 compared with Q4 2021
Measure	Q3 2021	Q4 2021	Change
Holders	68	71	+3
Shares	31.2M	32.9M	+1.68M (+5.4%)
Value	$483.9M	$390.4M	−$93.4M (−19.3%)

New holders (11)

Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to ALGS in Q4 2021
Institution	Shares	Value	% of portfolio
EcoR1 Capital, LLC	91,044	$1.08M	0.03%
Citadel Advisors LLC	16,016	$190.0K	0.00%
Gyon Technologies Capital Management, LP	15,557	$185.0K	0.03%
HRT Financial LP	13,797	$163.0K	0.00%
Invesco Ltd.	12,438	$147.0K	0.00%
ProShare Advisors LLC	10,177	$121.0K	0.00%
Wells Fargo & Company	8,563	$101.0K	0.00%
Ensign Peak Advisors, Inc	7,320	$87.0K	0.00%
Cubist Systematic Strategies, LLC	5,026	$60.0K	0.00%
Daiwa Securities Group Inc.	115	$1.00K	0.00%
Captrust Financial Advisors	51	$1.00K	0.00%

Sold out (8)

Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of ALGS in Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Sphera Funds Management Ltd.	249,197	$3.87M
Norges Bank	102,400	$1.59M
Altium Capital Management LP	33,492	$519.0K
Jump Financial, LLC	16,100	$250.0K
SG Americas Securities, LLC	8,383	$130.0K
O'Shaughnessy Asset Management, LLC	3,261	$51.0K
Point72 Hong Kong Ltd	1,357	$21.0K
Evolution Wealth Advisors, LLC	194	$3.00K